Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Bando

Showing results (101-110 of 186) with videos related to

Pageof 19
Sort By:
BMC Cancer|August 22, 2023
NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastasesShin Kobayashi, Hideaki Bando, Akinobu Taketomi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal CancerRona Yaeger, Daisuke Kotani, Sebastián Mondaca, et al.
BMC Cancer|April 22, 2020
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinomaHideaki Bando, Daisuke Kotani, Takahiro Tsushima, et al.
Cancer Immunology Research|December 12, 2024
Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of AdministrationShunsuke A Sakai, Koichi Saeki, SungGi Chi, et al.
British Journal of Cancer|May 5, 2025
Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling projectTaigo Kato, Masaki Shiota, Koshiro Nishimoto, et al.
Nature Reviews. Gastroenterology & Hepatology|March 15, 2024
Future direction of total neoadjuvant therapy for locally advanced rectal cancerYoshinori Kagawa, J Joshua Smith, Emmanouil Fokas, et al.
Clinical Colorectal Cancer|March 14, 2018
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO StudyEiji Oki, Takeshi Kato, Hideaki Bando, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal CancerSatoshi Fujii, Daisuke Kotani, Masahiro Hattori, et al.
Clinical Colorectal Cancer|March 29, 2024
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF<sup>V600E</sup>-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access ProgramDaisuke Kotani, Atsuo Takashima, Takeshi Kato, et al.
European Journal of Cancer (Oxford, England : 1990)|January 19, 2024
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluationRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
Pageof 19

Showing results (101-110 of 186) with videos related to

Sort By:
Pageof 19
BMC Cancer|August 22, 2023
NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastasesShin Kobayashi, Hideaki Bando, Akinobu Taketomi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal CancerRona Yaeger, Daisuke Kotani, Sebastián Mondaca, et al.
BMC Cancer|April 22, 2020
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinomaHideaki Bando, Daisuke Kotani, Takahiro Tsushima, et al.
Cancer Immunology Research|December 12, 2024
Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of AdministrationShunsuke A Sakai, Koichi Saeki, SungGi Chi, et al.
British Journal of Cancer|May 5, 2025
Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling projectTaigo Kato, Masaki Shiota, Koshiro Nishimoto, et al.
Nature Reviews. Gastroenterology & Hepatology|March 15, 2024
Future direction of total neoadjuvant therapy for locally advanced rectal cancerYoshinori Kagawa, J Joshua Smith, Emmanouil Fokas, et al.
Clinical Colorectal Cancer|March 14, 2018
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO StudyEiji Oki, Takeshi Kato, Hideaki Bando, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal CancerSatoshi Fujii, Daisuke Kotani, Masahiro Hattori, et al.
Clinical Colorectal Cancer|March 29, 2024
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF<sup>V600E</sup>-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access ProgramDaisuke Kotani, Atsuo Takashima, Takeshi Kato, et al.
European Journal of Cancer (Oxford, England : 1990)|January 19, 2024
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluationRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
Pageof 19